For immunochemical detection of RSV F protein
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

RSV F Protein Chimeric Monoclonal Antibody (Clone RSHZ19 (Felvizumab))

Item No. 37173

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Respiratory Syncytial Virus F Protein
  • Respiratory Syncytial Virus Fusion Protein
  • RSV Fusion Protein
Immunogen
Recombinant human-targeted RSV F
Clone Designation
RSHZ19 (Felvizumab)
Formulation (Request formulation change)
200 µg of protein A-affinity purified monoclonal antibody
Storage Buffer
PBS with 0.02% ProClin™ 300
Host
Chimeric Monoclonal Antibody
Isotype
IgG1ҡ
Applications
ELISA
Cross Reactivity
((+)) F protein
Species Reactivity
((+)) RSV
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    200 µg

    $473

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Respiratory syncytial virus (RSV) fusion (F) protein is a surface glycoprotein encoded by the F gene in RSV RNA.1 It is synthesized as an inactive precursor protein, F0, that undergoes proteolytic cleavage to release the F1 and F2 subunits, which are joined together by two disulfide bonds.2 Mature RSV F protein is composed of an N-terminal fusion peptide (FP), two heptad repeats (HRs), a transmembrane domain, and a cytoplasmic tail and assembles into homotrimers on the virus surface.1 Upon insertion of the FP in the target cell membrane, the HRs form a six-helical bundle (6-HB) that enables RSV to fuse with the target cell. RSV F protein is highly conserved between RSV subtypes A and B with approximately 90% amino acid identities.3 RSV is the most common causative agent of pediatric lower respiratory tract infections.4 Cayman's RSV F Protein Chimeric Monoclonal Antibody (Clone RSHZ19 (Felvizumab)) was produced recombinantly from the original humanized RSHZ19 antibody sequence, substituting the mouse antigen-binding domain with the rabbit IgG1 antigen-binding domain, and can be used for ELISA and in functional assays. The RSHZ19 antibody was generated by fusing human IgG1 constant domains to the antigen-binding domain of a mouse anti-RSV F protein monoclonal antibody.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Graham, B.S., and Anderson, L.J. Challenges and opportunities for respiratory syncytial virus vaccines. Curr. Top. Microbiol. Immunol. 372, 391-404 (2013).

    2. Day, N.D., Branigan, P.J., Liu, C., et al. Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol. J. 3, 34 (2006).

    3. Choi, S.-H., Park, K.S., and Kim, Y.-J. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015. J. Infect. Chemother. 25(7), 514-519 (2019).

    4. Nair, H., Nokes, D.J., Gessner, B.D., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375(9725), 1545-1455 (2010).

    5. Tempest, P.R., Bremner, P., Lambert, M., et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (N.Y.) 9(3), 266-271 (1991).